Related Experiment Video
Updated: Dec 15, 2025
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Novel monoclonal antibody against integrin α3 shows therapeutic potential for ovarian cancer
Feng-Yi Ke1,2, Wan-Yu Chen1, Ming-Chieh Lin3
1Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.
Abstract:
Ovarian cancer has a high recurrence rate after platinum-based chemotherapy. To improve the treatment of ovarian cancer and identify ovarian cancer-specific antibodies, we immunized mice with the human ovarian carcinoma cell line, SKOV-3, and generated hybridoma clones. Several rounds of screening yielded 30 monoclonal antibodies (mAbs) with no cross-reactivity to normal cells. Among these mAbs, OV-Ab 30-7 was found to target integrin α3 and upregulate p53 and p21, while stimulating the apoptosis of cancer cells. We further found that binding of integrin α3 by OV-Ab 30-7 impaired laminin-induced focal adhesion kinase phosphorylation. The mAb alone or in combination with carboplatin and paclitaxel inhibited tumor progression and prolonged survival of tumor-bearing mice. Moreover, immunohistochemical staining of ovarian patient specimens revealed higher levels of integrin α3 in cancer cells compared with normal cells. By querying online clinical databases, we found that elevated ITGA3 expression in ovarian cancer is associated with poor prognosis. Taken together, our data suggest that the novel mAb, OV-Ab 30-7, may be considered as a potential therapeutic for ovarian cancer.
Insights
A novel monoclonal antibody, OV-Ab 30-7, targets integrin α3, inducing ovarian cancer cell apoptosis and inhibiting tumor growth. This antibody shows potential as a new therapeutic for ovarian cancer, even in combination with existing treatments.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Ovarian cancer frequently recurs after chemotherapy.
- There is a need for novel therapeutic targets and agents for ovarian cancer treatment.
Purpose of the Study:
- To develop ovarian cancer-specific monoclonal antibodies (mAbs).
- To evaluate the therapeutic potential of a novel mAb, OV-Ab 30-7, targeting integrin α3.
Main Methods:
- Immunization of mice with SKOV-3 ovarian carcinoma cells to generate hybridomas.
- Screening of hybridoma clones to identify specific mAbs.
- In vitro and in vivo studies to assess the efficacy of OV-Ab 30-7.
- Immunohistochemical staining and clinical database analysis.
Main Results:
- 30 ovarian cancer-specific mAbs were generated; OV-Ab 30-7 targets integrin α3.
- OV-Ab 30-7 upregulates p53 and p21, induces cancer cell apoptosis, and inhibits focal adhesion kinase phosphorylation.
- OV-Ab 30-7 alone or with chemotherapy inhibited tumor progression and improved survival in mice.
- Elevated integrin α3 expression in ovarian tumors correlates with poor prognosis.
Conclusions:
- The novel mAb OV-Ab 30-7 demonstrates significant anti-tumor activity against ovarian cancer.
- Integrin α3 is a promising therapeutic target in ovarian cancer.
- OV-Ab 30-7 represents a potential new therapeutic strategy for ovarian cancer treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:56Treatment Resistant Cancers